P

Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403

Watchlist Manager
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
Watchlist
Price: 14.42 CNY -1.77% Market Closed
Market Cap: 13.7B CNY

Pacific Shuanglin Bio pharmacy Co Ltd's latest stock split occurred on Jun 4, 2025

The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.

Before the split, Pacific Shuanglin Bio pharmacy Co Ltd traded at 22.56 per share. Afterward, the share price was about 17.26.

The adjusted shares began trading on Jun 4, 2025. This was Pacific Shuanglin Bio pharmacy Co Ltd's 2nd stock split, following the previous one in Jul 27, 2020.

Last Splits:
Jun 4, 2025
1-for-1
Jul 27, 2020
1-for-1
Pre-Split Price
17.0039 22.56
Post-Split Price
17.26
Before
After
Last Splits:
Jun 4, 2025
1-for-1
Jul 27, 2020
1-for-1

Pacific Shuanglin Bio pharmacy Co Ltd
Stock Splits History

Pacific Shuanglin Bio pharmacy Co Ltd Stock Splits Timeline
Jun 4, 2025
Jun 4, 2025
Split 1-for-1
/1
Pre-Split Price
17.0039 22.56
Post-Split Price
17.26
Before
After
Jul 27, 2020
Jul 27, 2020
Split 1-for-1
/1
Pre-Split Price
28.0981 74.9297
Post-Split Price
28.8087
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
47.5 47.5 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.6 60.6 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Pacific Shuanglin Bio pharmacy Co Ltd
Glance View

Market Cap
13.7B CNY
Industry
Biotechnology

In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.

Intrinsic Value
24.69 CNY
Undervaluation 42%
Intrinsic Value
Price
P
Back to Top